AstraZeneca, Gatehouse Bio extend partnership to develop RNA therapeutics for heart failure
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Sep 22
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…
09 Sep 22
The campaign is called "Pure Flour from Europe: Your Organic and Sustainable Choice!" and it is co-funded by the…
09 Sep 22
Founded in 2017, the U.S.-headquartered coffee company currently boasts 27 farms spanning 6,652 acres in total landholdings and…
09 Sep 22
The company, which is the life science business of Merck, will use the investment to further ramp up…
08 Sep 22
Niko Suomalainen, Executive Chef at Emo, comments: "We're thrilled to be the first restaurant in Finland to offer New-Meat to…
08 Sep 22
The market for plant-based supplements worldwide is currently at $7.3 billion and is expected to surge past $11.5 billion by 2028…
08 Sep 22
The company’s investigational vaccine candidate is indicated for the prevention of invasive GBS disease in newborns and young…
08 Sep 22
The late-stage trial evaluated the Trop-2 directed antibody-drug conjugate in comparison to TPC chemotherapy in 543 patients having…
07 Sep 22
The European regulator found that the acquisition would provide Illumina with the ability and incentive to prevent GRAIL’s…
07 Sep 22
Emergence Therapeutics has secured license to use the GlycoConnect, HydraSpace and exatecan-based SYNtecan E linker-payload technologies to develop…